Evaluation of the Cross-Protective Efficacy of a Chimeric PRRSV Vaccine against Two Genetically Diverse PRRSV2 Field Strains in a Reproductive Model
| Autor: | Sang-Chul Kang, Yun-Hee Noh, Bumseok Kim, Amina Khatun, Seung-Chai Kim, Nadeem Shabir, Dong-Uk Lee, Chang-Gi Jeong, Won-Il Kim, In-Joong Yoon, Myeon-Sik Yang, Salik Nazki |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
animal diseases
Birth weight Immunology Reversion Virulence Viremia porcine reproductive and respiratory syndrome reproductive failure Article Virus Drug Discovery medicine Pharmacology (medical) PRRS vaccine Pharmacology biology medicine.disease Virology Vaccination reproductive model Infectious Diseases PRRSV biology.protein Medicine Gestation chimeric vaccine Antibody |
| Zdroj: | Vaccines Volume 9 Issue 11 Vaccines, Vol 9, Iss 1258, p 1258 (2021) |
| ISSN: | 2076-393X |
| DOI: | 10.3390/vaccines9111258 |
| Popis: | Despite the routine use of porcine reproductive and respiratory syndrome (PRRS)-modified live vaccines, serious concerns are currently being raised due to their quick reversion to virulence and limited cross-protection against divergent PRRS virus (PRRSV) strains circulating in the field. Therefore, a PRRS chimeric vaccine (JB1) was produced using a DNA-launched infectious clone by replacing open reading frames (ORFs) 3–6 with those from a mixture of two genetically different PRRSV2 strains (K07–2273 and K08–1054) and ORF1a with that from a mutation-resistant PRRSV strain (RVRp22) exhibiting an attenuated phenotype. To evaluate the safety and cross-protective efficacy of JB1 in a reproductive model, eight PRRS-negative pregnant sows were purchased and divided into four groups. Four sows in two of the groups were vaccinated with JB1, and the other 4 sows were untreated at gestational day 60. At gestational day 93, one vaccinated group and one nonvaccinated group each were challenged with either K07–2273 or K08–1054. All of the sows aborted or delivered until gestation day 115 (24 days post challenge), and the newborn piglets were observed up to the 28th day after birth, which was the end of the experiment. Overall, pregnant sows of the JB1-vaccinated groups showed no meaningful viremia after vaccination and significant reductions in viremia with K07–2273 and K08–1054, exhibiting significantly higher levels of serum virus-neutralizing antibodies than non-vaccinated sows. Moreover, the JB1-vaccinated groups did not exhibit any abortion due to vaccination and showed improved piglet viability and birth weight. The piglets from JB1-vaccinated sows displayed lower viral concentrations in serum and fewer lung lesions compared with those of the piglets from the nonvaccinated sows. Therefore, JB1 is a safe and effective vaccine candidate that confers simultaneous protection against two genetically different PRRSV strains. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|